Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer

Nguyen, Trang; Bartscht, Tobias; Schild, Steven E.; Rades, Dirk

doi:10.21873/anticanres.14117

Cited by 5 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further factors that were associated with survival were performance status, RPA class, the use of cranial radiotherapy in cohorts including untreated patients and the time from prostate cancer diagnosis to diagnosis of brain metastases or WBRT (3,18,19). Better performance status and lower RPA class were also associated with improved survival in this analysis.…”

Section: Methodsmentioning

confidence: 74%

Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy

Schröder

Windisch

Lütscher

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: To evaluate patients and treatment characteristics as well as clinical outcome in patients with intracranial metastases from prostate cancer (PCA) treated with palliative radiotherapy. Patients and Methods: Fifteen patients treated for intracranial metastases of PCA were identified. The median age of patients was 69 years. 80% of patients received whole brain radiotherapy and 20% received partial brain radiotherapy. Clinical outcome was assessed. Univariate analysis was performed to analyze the impact of patient specific parameters on survival. Results: There was no >G2 acute or any late toxicity. Median time from the first diagnosis of PCA to first diagnosis of intracranial metastases was 62 months (range=15-160 months). Median survival from first diagnosis of intracranial metastases was 14 weeks (range=0-126 weeks) and 6 weeks (range=0-47 weeks) from the start of radiotherapy. In univariate analysis, survival was significantly better for patients with an Eastern Cooperative Oncology Group (ECOG) performance status 1 compared to ECOG 2-3 [18 weeks (range=5-47 weeks) vs. 3 weeks (range=0-21 weeks), p=0.030] and Recursive Partitioning Analysis (RPA) class 2 compared to RPA class 3 [18 weeks (range=5-47 weeks) vs. 6 weeks (range=0-21 weeks), p=0.045]. Conclusion: Overall survival of the patients with wide-spread intracranial metastases from PCA was poor. The decision for a radiotherapy should be done on individual patient basis.

show abstract

Section: Methodsmentioning

confidence: 74%

Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy

Schröder

Windisch

Lütscher

et al. 2022

In Vivo

View full text Add to dashboard Cite

show abstract

“…The manual reference search conducted for each of the 23 selected articles resulted in the selection of an additional four articles. Ultimately, a total of 27 articles were included in this analysis, spanning the period from 1976 to 2021 [ 4 , 5 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ].…”

Section: Resultsmentioning

confidence: 99%

“…In three studies, the locations of synchronous metastases were not reported by specific location but instead reported as visceral metastases. Each of those particular studies reported high rates of concurrent visceral metastases ranging from 59% to 81% [ 12 , 37 , 40 ].…”

Section: Resultsmentioning

confidence: 99%

“…Amongst all metastatic sites from prostate cancer, BM are associated with particularly poor outcome, with the most recent available patient series suggesting a median survival ranging from two to twelve months following diagnosis [ 4 , 11 , 12 ]. Furthermore, BM from prostate cancer are also associated with a high symptom burden [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis

Rajeswaran

Muzio

Briones

et al. 2022

JCM

View full text Add to dashboard Cite

Brain metastases (BM) are perceived as a rare complication of prostate cancer associated with poor outcome. Due to limited published data, we conducted a literature review regarding incidence, clinical characteristics, treatment options, and outcomes of patients with prostate cancer BM. A literature analysis of the PubMed, MEDLINE, and EMBASE databases was performed for full-text published articles on patients diagnosed with BM from prostate cancer. Eligible studies included four or more patients. Twenty-seven publications were selected and analyzed. The sources of published patient cohorts were retrospective chart reviews, administrative healthcare databases, autopsy records, and case series. BM are rare, with an incidence of 1.14% across publications that mainly focus on intraparenchymal metastases. Synchronous visceral metastasis and rare histological prostate cancer subtypes are associated with an increased rate of BM. Many patients do not receive brain metastasis-directed local therapy and the median survival after BM diagnosis is poor, notably in patients with multiple BM, dural-based metastases, or leptomeningeal dissemination. Overall, prostate cancer BM are rare and associated with poor prognosis. Future research is needed to study the impact of novel prostate cancer therapeutics on BM incidence, to identify patients at risk of BM, and to characterize molecular treatment targets.

show abstract

“…Studies have shown that patients with poor general condition have short survival time and are independent prognostic risk factors for advanced NSCLC 14 Behavior state score (performance score, PS, or Karnofsky Performance Score, KPS) are widely used to assess general condition of cancer patients. Nguyen T et al 15 showed in a study of 21 elderly (>65 years old) patients with advanced cancer that behavioral performance is an important index affecting the survival rate of patients. In our study, univariate and multivariate analyses showed that PS score was related to survival time.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors of 112 elderly patients with advanced non-small cell lung cancer

Ran¹,

Liu

2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: In this study we retrospectively analyzed the prognostic factors of patients with advanced non-small cell lung cancer (NSCLC). Methods: Clinical data of 112 patients with advanced NSCLC treated in the tumor center of our hospital from January 2016 to December 2017 were analyzed retrospectively, follow up the survival of patients, the effects of gender, age, tumor stage, pathological type, performance status (PS) score, smoking history and treatment on the survival of elderly patients with advanced NSCLC were analyzed. Results: The median survival time was 12.0 months, and the median age was 74 years. The 3-year survival rate after confirmation of advanced lung cancer was 6.25%. Kaplan Meier univariate analysis showed that age, PS score, smoking status and treatment correlated with the prognosis(P<0.05). Cox multivariate analysis showed that age >70 years, PS score>2, smoking and no targeted therapy were independent adverse prognostic factors for elderly patients with advanced NSCLC(P<0.05). Conclusions: Age, PS score, smoking and treatment mode affect the prognosis and survival of elderly patients with advanced NSCLC. Effective treatment should be given according to the principle of evidence-based medicine. doi: https://doi.org/10.12669/pjms.38.6.5457 How to cite this:Ran F, Liu Q. Prognostic factors of 112 elderly patients with advanced non-small cell lung cancer. Pak J Med Sci. 2022;38(6):---------. doi: https://doi.org/10.12669/pjms.38.6.5457 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer

Cited by 5 publications

References 13 publications

Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy

Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy

Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis

Prognostic factors of 112 elderly patients with advanced non-small cell lung cancer

Contact Info

Product

Resources

About